Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)-Reference-Cited by-同舟云学术

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Published:2018-07-26 Issue:9 Volume:103 Page:1422-1432
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Bringhen Sara,Milan Alberto,Ferri Claudio,Wäsch Ralph,Gay Francesca,Larocca Alessandra,Salvini Marco,Terpos Evangelos,Goldschmidt Hartmut,Cavo Michele,Petrucci Maria Teresa,Ludwig Heinz,Auner Holger W.,Caers Jo,Gramatzki Martin,Boccadoro Mario,Einsele Hermann,Sonneveld Pieter,Engelhardt Monika

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma;International Journal of Molecular Sciences;2024-07-16

2. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium;Journal of Thrombosis and Haemostasis;2024-07

3. Major cardiovascular events in long-term multiple myeloma survivors: a Korean case–control study (the CAREMM-2105 study);Clinical and Experimental Medicine;2024-06-12

4. Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity;British Journal of Pharmacology;2024-04-28

5. Major cardiovascular events in long-term multiple myeloma survivors: A Korean case- control study (The CAREMM-2105 study);2024-04-04